Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NovoSeven for bleeding after HSCT
NCT01564563Phase 2Terminated
- Sponsor
- Novo Nordisk
- Start
- Jun 2002
- Primary completion
- Oct 2003
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of coagulation factor VIIa in hemorrhage (3 arms), sponsored by Novo Nordisk. Primary endpoint: Effect on bleeding, defined as change in bleeding score. Started Jun 2002; status: terminated.
02
Drugs
coagulation factor VIIa
03
Conditions
hemorrhage
Beyond the preview
Go deeper on NCT01564563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01564563.